MSC7 Antibody

Definition and Context

The MSC7 antibody is a monoclonal antibody (mAb) developed to target carbonic anhydrase IX (CAIX), a transmembrane enzyme overexpressed in hypoxic tumor microenvironments . It belongs to a panel of 12 antibodies (MSC1–MSC12) designed for diagnostic and therapeutic applications in cancers linked to hypoxia, including renal, breast, bladder, and non-small cell lung cancers .

Table 1: CDR Sequences of MSC7 Antibody

Source: Patent WO2011139375A1 .

Functional Properties

• Target Specificity: Binds human CAIX with high affinity, inhibiting its enzymatic activity .

• Cross-Reactivity: Recognizes both human and mouse CAIX isoforms .

• Mechanism of Action:

  • Blocks CAIX-mediated pH regulation in hypoxic tumors, disrupting tumor survival .

  • Triggers immune-mediated tumor cell lysis via ADCC and CDC .

Therapeutic Efficacy

• Preclinical Studies:

  • Demonstrated potent anti-tumor activity in xenograft models of renal and breast cancers .

  • Reduced tumor growth by 50% in murine models when co-administered with mesenchymal stromal cells (MSCs) engineered for targeted delivery .

Diagnostic Applications

• Biomarker Detection: Used in immunohistochemistry (IHC) to identify hypoxic regions in solid tumors .

Table 2: Cancer Types Targeted by MSC7 Antibody

Mechanistic Insights

• CAIX Inhibition: Suppresses extracellular acidification, impairing tumor cell proliferation and metastasis .

• Immune Activation: Engages Fcγ receptors on NK cells and macrophages, promoting tumor cell phagocytosis .

Challenges and Future Directions

• Delivery Optimization: Engineering MSCs for localized antibody secretion to minimize off-target effects .

• Resistance Mechanisms: Addressing potential antigen escape variants in hypoxic niches .

References

1. Monoclonal antibodies in MS: mechanisms of action - PMC .

2. Mesenchymal stromal cells restrain the Th17 cell response via L-amino-acid oxidase .

3. Antibodies directed against carbonic anhydrase IX (WO2011139375A1) .

4. Engineered MSCs combating SARS-CoV-2 .

5. Stem Cells As an Emerging Platform for Antibody Therapy .